Log In
Print
BCIQ
Print
Print this Print this
 

Fulyzaq, crofelemer (NP-303)

Also known as: CRO-ID (TRN-002)

  Manage Alerts
Collapse Summary General Information
Company Napo Pharmaceuticals Inc.
DescriptionPurified proanthocyanidin oligomer extracted from the bark latex of the Amazonian tree Croton lechleri that acts as a partial antagonist of cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channel
Molecular Target Cystic fibrosis transmembrane conductance regulator (CFTR) ; Chloride channel
Mechanism of ActionCl channel antagonist; CFTR inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiarrhea (infectious)
Indication DetailsTreat acute watery diarrhea; Treat chronic diarrhea associated with HIV/AIDS who use anti-retroviral drugs
Regulatory Designation U.S. - Fast Track (Treat chronic diarrhea associated with HIV/AIDS who use anti-retroviral drugs);
U.S. - Priority Review (Treat chronic diarrhea associated with HIV/AIDS who use anti-retroviral drugs);
U.S. - Special Protocol Assessment (Treat chronic diarrhea associated with HIV/AIDS who use anti-retroviral drugs)
Partner Glenmark Pharmaceuticals Ltd.; Luye Pharma Group Ltd.; Valeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$15,624.0M

$14,789.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today